A Randomized, Parallel-Group, Open-Label Trial of Recombinant Human Erythropoietin vs Preoperative Autologous Donation in Primary Total Joint Arthroplasty. Effect on Postoperative Vigor and Handgrip Strength

Journal of Arthroplasty

Volumn 22, Issue 3, 2007, Pages 325-333

  Keating, E Michael ^a   Callaghan, John J ^b   Ranawat, Amar S ^c   Bhirangi, Kiran ^d   Ranawat, Chitranjan S ^c  

^a Kendrick Memorial Hospital   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d Ortho Biotech Products LP   (United States)

Author keywords

epoetin alfa; preoperative autologous donation; strength; transfusion; vigor

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; GRIP STRENGTH; HAND GRIP; HEART CATHETERIZATION; HEART INFARCTION; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOKALEMIA; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; THROMBOPHLEBITIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URTICARIA; VOMITING;

ACTIVITIES OF DAILY LIVING; AGED; ANEMIA; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD TRANSFUSION, AUTOLOGOUS; EPOETIN ALFA; FEMALE; HAND STRENGTH; HEALTH STATUS; HEALTH STATUS INDICATORS; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD;

EID: 33947720037     PISSN: 08835403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arth.2006.11.002     Document Type: Article

References (33)

1. Toy P.T., Kaplan E.B., McVay P.A., et al. Blood loss and replacement in total hip arthroplasty: a multicenter study. The preoperative autologous blood donation study group. Transfusion 32 (1992) 63
2. Churchill W.H., McGurk S., Chapman R.H., et al. The collaborative hospital transfusion study: variations in use of autologous blood account for hospital differences in red cell use during primary hip and knee surgery. Transfusion 38 (1998) 530
3. Bierbaum B.E., Callaghan J.J., Galante J.O., et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 81 (1999) 2
4. Linden J.V., and Kruskall M.S. Autologous blood: always safer?. [editorial]. Transfusion 37 (1997) 455
5. Goodnough L.T. Autologous blood donation. Crit Care 8 Suppl 2 (2004) S49
6. Domen R.E. Adverse reactions associated with autologous blood transfusion: evaluation and incidence at a large academic hospital. Transfusion 38 (1998) 296
7. Goldman M., Remy-Prince S., Trepanier A., et al. Autologous donation error rates in Canada. Transfusion 37 (1997) 523
8. Etchason J., Petz L., Keeler E., et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 332 (1995) 719
9. Billote D.B., Glisson S.N., Green D., et al. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am 84-A (2002) 1299
10. Rosencher N., Kerkkamp H.E., Macheras G., et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 43 (2003) 459
11. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 341 (1993) 1227
12. de Andrade J.R., Jove M., Landon G., et al. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 25 (1996) 533
13. Faris P.M., Ritter M.A., and Abels R.I. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 78 (1996) 62
14. Goldberg M.A., McCutchen J.W., Jove M., et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 25 (1996) 544
15. Tamir L., Fradin Z., Fridlander M., et al. Recombinant human erythropoietin reduces allogeneic blood transfusion requirements in patients undergoing major orthopedic surgery. Haematologia (Budap) 30 (2000) 193
16. Feagan B.G., Wong C.J., Kirkley A., et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 133 (2000) 845
17. Cushner F.D., Locker J.R., Hanssen A.D., et al. Use of recombinant human erythropoietin in two-stage total knee arthroplasty for infection. Clin Orthop (2001) 116
18. Rauh M.A., Bayers-Thering M., LaButti R.S., et al. Preoperative administration of epoetin alfa to total joint arthroplasty patients. Orthopedics 25 (2002) 317
19. Lee G.C., Pagnano M.W., Jacofsky D.J., et al. Use of erythropoietin in two-stage reimplantation total hip arthroplasty. Clin Orthop (2003) 49
20. Stowell C.P., Chandler H., Jove M., et al. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics 22 (1999) s105
21. Gombotz H., Gries M., Sipurzynski S., et al. Preoperative treatment with recombinant human erythropoietin or predeposit of autologous blood in women undergoing primary hip replacement. Acta Anaesthesiol Scand 44 (2000) 737
22. Lofthouse R.A., Boitano M.A., Davis J.R., et al. Preoperative administration of epoetin alfa to reduce transfusion requirements in elderly patients having primary total hip or knee reconstruction. J South Orthop Assoc 9 (2000) 175
23. Bezwada H.P., Nazarian D.G., Henry D.H., et al. Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am 85 (2003) 1795
24. Pierson J.L., Hannon T.J., and Earles D.R. A blood-conservation algorithm to reduce blood transfusions after total hip and knee arthroplasty. J Bone Joint Surg Am 86-A (2004) 1512
25. Ross S.D., Fahrbach K., Frame D., et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 25 (2003) 1786
26. Grossman H.A., Goon B., Bowers P., et al. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. J Acquir Immune Defic Syndr 34 (2003) 368
27. Keating E.M., Ranawat C.S., and Cats-Baril W. Assessment of postoperative vigor in patients undergoing elective total joint arthroplasty: a concise patient- and caregiver-based instrument. Orthopedics 22 (1999) s119
28. Mathiowetz V. Comparison of Rolyan and Jamar dynamometers for measuring grip strength. Occup Ther Int 9 (2002) 201
29. 2006 ASP drug pricing files. Available at:. http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp#TopOfPa ge [Accessed September 28, 2006]
30. Laird J. Erythropoietin: can we afford to use it? Can we afford not to?. Transfus Med 16 (2006) 204
31. Morgan T.O. Blood conservation: the CEO perspective. J Cardiothorac Vasc Anesth 18 (2004) 15
32. Couvret C., Laffon M., Baud A., et al. A restrictive use of both autologous donation and recombinant human erythropoietin is an efficient policy for primary total hip or knee arthroplasty. Anesth Analg 99 (2004) 262
33. Munin M.C., Rudy T.E., Glynn N.W., et al. Early inpatient rehabilitation after elective hip and knee arthroplasty. JAMA 279 (1998) 847